Clinical Trial Update: 7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating Sucraid (sacrosidase) for CSID symptoms across low, moderate, and normal sucrase levels has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Sucrase-isomaltase Deficiency

Drugs mentioned

• SUCRAID (sacrosidase)

Snippet

Sponsor: QOL Medical, LLC | Conditions: Congenital Sucrase-Isomaltase Deficiency, CSID | Phase 4 | Status: TERMINATED